---
title: "Haoxi Health Technology Limited (HAO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HAO.US.md"
symbol: "HAO.US"
name: "Haoxi Health Technology Limited"
industry: "Media"
datetime: "2026-05-20T18:41:09.945Z"
locales:
  - [en](https://longbridge.com/en/quote/HAO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HAO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HAO.US.md)
---

# Haoxi Health Technology Limited (HAO.US)

## Company Overview

Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry.

| Item | Detail |
|------|--------|
| Industry | Media |
| Exchange | US Market |
| Website | [www.haoximedia.com](https://www.haoximedia.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.50)**

**Industry**: Media

| Metric | Value |
|--------|-------|
| Industry Ranking | 61 / 120 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.85% |  |
| Net Profit YoY | -1027.27% |  |
| P/B Ratio | 0.05 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 832213.59 |  |
| Revenue | 42677684.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -15.98% | E |
| Profit Margin | -6.50% | D |
| Gross Margin | 4.72% | E |
| Revenue YoY | -12.85% | E |
| Net Profit YoY | -1027.27% | E |
| Total Assets YoY | -6.37% | D |
| Net Assets YoY | -14.86% | E |
| Cash Flow Margin | 121.73% | B |
| OCF YoY | -12.85% | E |
| Turnover | 2.00 | A |
| Gearing Ratio | 22.77% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Haoxi Health Technology Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.85%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1027.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.05",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "832213.59",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "42677684.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-15.98%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-6.50%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "4.72%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.85%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1027.27%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.37%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-14.86%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "121.73%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-12.85%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "2.00",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.77%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.30 | 48/120 | 15.49 | 11.61 | 2.20 |
| PB | 0.05 | 4/120 | 3.49 | 0.24 | 0.19 |
| PS (TTM) | 0.02 | 2/120 | 1.53 | 0.11 | 0.07 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | MNTN (MNTN.US) | A | A | A | A | A | A |
| 02 | New York Times (NYT.US) | A | B | A | B | B | B |
| 03 | Trade Desk (TTD.US) | A | B | C | D | B | B |
| 04 | DoubleVerify (DV.US) | B | B | B | A | B | B |
| 05 | Criteo SA (CRTO.US) | B | D | A | C | C | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HAO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HAO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HAO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HAO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**